Skip to content
Screener

Bio-Rad Laboratories BIO Total Liabilities

Total Liabilities at other companies

Abbott logo
AbbottABT
$4.61B
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$767M
MaxCyte logo
MaxCyteMXCT
$26.59M-13.0%
Quanterix Corporation logo
Quanterix CorporationQTRX
$84.53M+5.5%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$3.78B+9.0%
Revvity logo
RevvityRVTY
$4.81B+1.9%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$9.3B+30.0%
Enterprise value$9.78B+19.3%
P/E55.1×+32.7×
P/S3.6×+0.8×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000012208-26-000035
LIABILITIES AND STOCKHOLDERS’ EQUITYMarch 31, 2026 / (Unaudited)December 31, 2025
Deferred income taxes881.81,059.4
Operating lease liabilities138.6145.7
Other long-term liabilities198.4199.1
Total liabilities2,938.73,122.9
Stockholders’ equity:
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,199,880 and 25,199,760 as of March 31, 2026 and December 31, 2025, respectively; shares outstanding - 21,762,498 and 21,924,284 as of March 31, 2026 and December 31, 2025, respectively
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,065,990 as of March 31, 2026 and 5,066,110 as of December 31, 2025, respectively

Item 1. Financial Statements (Unaudited)

FAQ

What is Bio-Rad Laboratories's total liabilities?
Bio-Rad Laboratories (BIO) reported total liabilities of $2.94B in Q1 2026.
How has Bio-Rad Laboratories's total liabilities changed year-over-year?
Bio-Rad Laboratories's total liabilities increased by 3.2% year-over-year, from $2.85B to $2.94B.
What is the long-term trend for Bio-Rad Laboratories's total liabilities?
Over 5 years (2020 to 2025), Bio-Rad Laboratories's total liabilities has grown at a 0.2% compound annual growth rate (CAGR), from $3.09B to $3.12B.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Bio-Rad Laboratories's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude